We are live on ! Find out more
ECYT

Endocyte, Inc. Common Stock
ECYT

Delisted

ECYT was delisted on the 20th of December, 2018.

Back to rankings

100 hedge funds and large institutions have $106M invested in Endocyte, Inc. Common Stock in 2014 Q4 according to their latest regulatory filings, with 22 funds opening new positions, 26 increasing their positions, 36 reducing their positions, and 21 closing their positions.

New
Increased
Maintained
Reduced
Closed

6% more capital invested

Capital invested by funds: $101M → $106M (+$5.7M)

5% more first-time investments, than exits

New positions opened: 22 | Existing positions closed: 21

1% less funds holding

Funds holding: 101 → 100 (-1)

28% less repeat investments, than reductions

Existing positions increased: 26 | Existing positions reduced: 36

28% less call options, than puts

Call options by funds: $1.88M | Put options by funds: $2.61M

Holders
100
Holders Change
-1
Holders Change %
-0.99%
% of All Funds
2.67%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
22
Increased
26
Reduced
36
Closed
21
Calls
$1.88M
Puts
$2.61M
Net Calls
-$729K
Net Calls Change
+$2.87M

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$2.59M
2
NI
Numeric Investors
Massachusetts
+$2.51M
3
Deutsche Bank
Deutsche Bank
Germany
+$1.76M
4
California Public Employees Retirement System
California Public Employees Retirement System
California
+$1.01M
5
AQR Capital Management
AQR Capital Management
Connecticut
+$958K

Top Sellers

Rank Fund Capital Flow
1
BB
BB Biotech
Switzerland
-$4.16M
2
ARTA
A.R.T. Advisors
New York
-$1.89M
3
Citadel Advisors
Citadel Advisors
Florida
-$1.34M
4
GC
Guggenheim Capital
Illinois
-$1.32M
5
American Century Companies
American Century Companies
Missouri
-$815K
Name Holding Trade Value Shares
Change 		Change in
Stake
Fidelity Investments
1
Fidelity Investments
Massachusetts
$31.5M -$640K -105,008 -2%
BFA
2
BlackRock Fund Advisors
California
$9.76M +$896K +146,971 +10%
Vanguard Group
3
Vanguard Group
Pennsylvania
$6.42M +$151K +24,795 +2%
PA
4
Pinnacle Associates
New York
$6.23M +$201K +33,035 +3%
Millennium Management
5
Millennium Management
New York
$5.61M +$605K +99,249 +13%
NI
6
Numeric Investors
Massachusetts
$5.12M +$2.51M +411,083 +102%
State Street
7
State Street
Massachusetts
$3.7M -$15.5K -2,536 -0.4%
Renaissance Technologies
8
Renaissance Technologies
New York
$3.38M +$2.59M +425,705 +381%
Northern Trust
9
Northern Trust
Illinois
$2.48M -$93K -15,250 -4%
BIT
10
BlackRock Institutional Trust
California
$2.44M -$63.3K -10,385 -3%
Susquehanna International Group
11
Susquehanna International Group
Pennsylvania
$2.18M +$507K +83,242 +32%
Deutsche Bank
12
Deutsche Bank
Germany
$2.04M +$1.76M +288,657 +806%
CRC
13
Curi RMB Capital
Illinois
$1.38M -$610 -100 -0%
Bank of New York Mellon
14
Bank of New York Mellon
New York
$1.36M -$72.4K -11,871 -5%
AQR Capital Management
15
AQR Capital Management
Connecticut
$1.33M +$958K +157,200 +286%
Geode Capital Management
16
Geode Capital Management
Massachusetts
$1.25M +$1.55K +255 +0.1%
California Public Employees Retirement System
17
California Public Employees Retirement System
California
$884K +$1.01M +164,900 New
TCIM
18
TIAA CREF Investment Management
New York
$843K -$85.3K -14,002 -9%
HCMT
19
Highland Capital Management (Texas)
Texas
$837K +$812K +133,139 New
BCM
20
Bridgeway Capital Management
Texas
$786K +$761K +124,900 New
MERSOM
21
Municipal Employees' Retirement System of Michigan
Michigan
$739K +$260K +42,690 +57%
BIM
22
BlackRock Investment Management
Delaware
$685K -$6.45K -1,058 -1%
TI
23
Trexquant Investment
Connecticut
$637K +$618K +101,400 New
ERSOT
24
Employees Retirement System of Texas
Texas
$635K – – –
Citadel Advisors
25
Citadel Advisors
Florida
$586K -$1.34M -219,477 -70%
1
2 3 4 5

ECYT Hedge Fund Activity: Q4 2014 in Review

100 of the 3,750 institutional investors tracked by Wall St. Rank reported a position in Endocyte, Inc. Common Stock (ECYT) for Q4 2014, worth a combined $106M — up 5.7% from $101M a quarter earlier.

Buyers outnumbered sellers: 22 funds opened new ECYT positions and 21 closed out — a net gain of 1 holder — while 26 added to existing stakes and 36 trimmed.

The largest buyer was Renaissance Technologies, adding an estimated $2.59M. The largest seller was BB Biotech, exiting entirely with an estimated $4.16M sold.

  • 100 institutional investors held Endocyte, Inc. Common Stock (ECYT) as of Q4 2014, down from 101 in Q3 2014.
  • Funds reported $106M of Endocyte, Inc. Common Stock stock for Q4 2014, up 5.7% quarter-over-quarter.
  • 22 funds opened new Endocyte, Inc. Common Stock positions in Q4 2014 and 21 closed out, a net change of +1 holder.
  • The largest Endocyte, Inc. Common Stock buyer in Q4 2014 was Renaissance Technologies, an estimated $2.59M added.
  • The largest Endocyte, Inc. Common Stock seller in Q4 2014 was BB Biotech, an estimated $4.16M sold.

Based on aggregated 13F filings for Q4 2014.